AYTU

Aytu BioScience Inc

AYTU.US aytubio.com
2.05
+0.00 (+0.00%)
USD · NASDAQ
52-week range
1.65
3.07
Trading at 28% of the 52-week range
Market Cap
22.75M
P/E Ratio
0.00
Forward P/E
27.47
Book Value
3.27
Div. Yield
N/A
% Institutions
35.96%
% Insiders
8.27%

1 Year

-10.1%

3 Year

+21.3%

10 Year

-100.0%
Description

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Company Information

Company Name
Aytu BioScience Inc
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US0547548588
CIK: 0001385818
CUSIP: 054754205
Currency: USD
Full Time Employees: 82
Phone: 720 437 6580
Website: aytubio.com
Fiscal Year End: June
IPO Date: Feb 01, 2017
Description:

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Address:

Denver Corporate Center III, Denver, CO, United States, 80237

People

Directors & Officers

Name Title Year Born
Mr. Joshua R. Disbrow CEO & Director 1975
Mr. Ryan J. Selhorn CPA CFO, Corporate Secretary & Treasurer 1982
Mr. Jarrett T. Disbrow Ph.D. Chief Business Officer 1975
Mr. Greg Pyszczymuka Chief Commercial Officer 1979
Ms. Margaret Cabano Vice President of Operations NA
Dr. Gerwin Westfield Ph.D. Senior Vice President of Scientific Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 28, 2025 Joshua R Disbrow N/A Purchase 15.00K $1.30 $19.50K
Jun 16, 2023 Greg Pyszczymuka N/A Purchase 12.00K $1.87 $22.44K
Jun 14, 2023 Joshua R Disbrow N/A Purchase 14.00K $1.86 $26.04K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Nantahala Capital Management, LLC 1.09M Mar 31, 2026 10.13% $0.11 0.00%
Stonepine Capital Management Llc 792.29K Mar 31, 2026 7.38% $0.87 -2.63%
Awm Investment Company Inc 619.57K Mar 31, 2026 5.77% $0.19 0.00%
Vanguard Capital Management, LLC 261.15K Mar 31, 2026 2.43% $0.00 0.00%
CROWN ADVISORS MANAGEMENT, INC. 200.00K Jun 30, 2026 1.86% $0.24 37.93%
Diadema Partners LP 148.55K Jun 30, 2026 1.38% $0.04 -57.93%
Two Sigma Investments LLC 121.97K Mar 31, 2026 1.14% $0.00 13.85%
Renaissance Technologies Corp 93.72K Mar 31, 2026 0.87% $0.00 4.57%
Persistent Asset Partners Limited 92.90K Mar 31, 2026 0.87% $0.09 16.98%
Geode Capital Management, LLC 92.64K Mar 31, 2026 0.86% $0.00 25.02%
Arete Wealth Advisors, LLC 49.55K Mar 31, 2026 0.46% $0.30 0.00%
Vanguard Fiduciary Trust Co 47.05K Mar 31, 2026 0.44% $0.00 0.00%
Dimensional Fund Advisors, Inc. 45.33K Jun 30, 2026 0.42% $0.00 3.99%
Citadel Advisors Llc 36.84K Mar 31, 2026 0.34% $0.00 136.90%
Bellevue Asset Management, LLC 25.01K Mar 31, 2026 0.23% $0.03 0.00%
BlackRock Inc 22.79K Mar 31, 2026 0.21% $0.00 0.00%
XTX Topco Ltd 21.58K Mar 31, 2026 0.20% $0.00 -16.54%
Northern Trust Corp 19.17K Mar 31, 2026 0.18% $0.00 0.00%
Acadian Asset Management LLC 10.24K Mar 31, 2026 0.10% $0.00 0.00%
Daytona Street Capital LLC 10.00K Jun 30, 2026 0.09% $0.02 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 169.00K 1.57% ▲ 0.00% Jul 31, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 92.15K 0.86% ▲ 0.00% Jul 31, 2026
3 Fidelity Extended Market Index 48.91K 0.46% ▼ 0.19% Jul 31, 2026
4 Perritt MicroCap Opportunities Investor 20.00K 0.19% ▲ 0.00% Dec 31, 2025
5 Northern Trust Extended Eq Market Idx 15.32K 0.14% ▲ 0.00% Jun 30, 2026
6 NT Ext Equity Mkt Index Fund - Lending 15.32K 0.14% ▲ 0.00% Jun 30, 2026
7 Stewardship Partners US Multi Tax-Eff 14.84K 0.14% ▲ 0.00% Jun 30, 2026
8 Fidelity Series Total Market Index 14.10K 0.13% ▲ 0.00% Jul 31, 2026
9 Spartan Extended Market Index Pool F 13.79K 0.13% ▲ 0.66% Jul 31, 2026
10 NT Ext Equity Mkt Index Fund - NL 10.03K 0.09% ▲ 701.20% Jun 30, 2026

Financial Highlights

Market Cap: $22.75M
EBITDA: $-2.63M
PEG Ratio: $0.00
Book Value: $3.27
Earnings/Share: $-4.48
Profit Margin: -60.17%
Operating Margin: -32.74%
ROA (TTM): -3.66%
ROE (TTM): -97.42%
Revenue (TTM): $56.60M
Revenue/Share (TTM): $6.16
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -32.70%

Valuation Metrics

Enterprise Value: $18.61M
Trailing P/E: 0.00
Forward P/E: 27.47

Shares Statistics

Shares Outstanding: 10.73M
Shares Float: 7.55M
% Insiders: 8.27%
% Institutions: 35.96%
Short % Float: 3.49%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$66.38M
Cost of Goods Sold
adjust
$-20.55M
Gross Profit
subtotal
$45.83M
SG&A
adjust
$-17.38M
R&D
adjust
$-1.33M
Other Operating Expense
adjust
$-34.95M
Operating Income
subtotal
$-7.83M
Other / Non-Operating Items
adjust
$-5.74M
Net Income
subtotal
$-13.56M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AYTU.US!